Riverhead Capital Management LLC cut its position in shares of Amsurg Corp. (NASDAQ:AMSG) by 96.7% during the third quarter, according to its most recent disclosure with the SEC. The firm owned 2,200 shares of the company’s stock after selling 64,006 shares during the period. Riverhead Capital Management LLC’s holdings in Amsurg Corp. were worth $147,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. Emerald Acquisition Ltd. purchased a new stake in Amsurg Corp. during the second quarter valued at $106,000. Rockefeller Financial Services Inc. purchased a new stake in Amsurg Corp. during the third quarter valued at $106,000. DekaBank Deutsche Girozentrale raised its stake in Amsurg Corp. by 249.1% in the third quarter. DekaBank Deutsche Girozentrale now owns 2,590 shares of the company’s stock valued at $171,000 after buying an additional 1,848 shares during the last quarter. Smith Asset Management Group LP raised its stake in Amsurg Corp. by 51.7% in the third quarter. Smith Asset Management Group LP now owns 2,610 shares of the company’s stock valued at $175,000 after buying an additional 890 shares during the last quarter. Finally, CENTRAL TRUST Co purchased a new stake in Amsurg Corp. during the third quarter valued at $175,000. Institutional investors own 98.67% of the company’s stock.
Amsurg Corp. (NASDAQ:AMSG) remained flat at $67.75 on Friday. The firm’s 50-day moving average is $64.49 and its 200 day moving average is $69.95. Amsurg Corp. has a 52-week low of $57.32 and a 52-week high of $84.71.
Amsurg Corp. (NASDAQ:AMSG) last posted its quarterly earnings results on Tuesday, November 1st. The company reported $1.13 EPS for the quarter, meeting the Zacks’ consensus estimate of $1.13. The business earned $822.20 million during the quarter, compared to the consensus estimate of $770.29 million. Amsurg Corp. had a return on equity of 8.05% and a net margin of 6.06%. Amsurg Corp.’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.03 earnings per share. Analysts anticipate that Amsurg Corp. will post $4.30 earnings per share for the current year.
Several equities research analysts have recently weighed in on AMSG shares. KeyCorp reaffirmed a “positive” rating and issued a $87.00 target price on shares of Amsurg Corp. in a report on Tuesday, October 4th. Wells Fargo & Company raised shares of Amsurg Corp. from a “market perform” rating to an “outperform” rating in a report on Wednesday, November 2nd. They noted that the move was a valuation call. Cantor Fitzgerald set a $90.00 price objective on shares of Amsurg Corp. and gave the stock a “buy” rating in a report on Wednesday, November 2nd. Zacks Investment Research raised shares of Amsurg Corp. from a “sell” rating to a “hold” rating in a report on Friday, November 4th. Finally, Mizuho lowered shares of Amsurg Corp. from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $95.00 to $71.00 in a report on Wednesday, November 9th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Amsurg Corp. has a consensus rating of “Buy” and a consensus target price of $88.70.
About Amsurg Corp.
AmSurg Corp. is a surgical center and physician services company. The Company is an owner and operator of ambulatory surgery centers (ASCs) in the United States. The Company is also a provider of outsourced physician services in the areas of anesthesiology, children’s services, emergency medicine and radiology.
Want to see what other hedge funds are holding AMSG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amsurg Corp. (NASDAQ:AMSG).